These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
A Comperehensive Drug Repurposing Study for Covid19 Treatment: Novel Putative DHODH Inhibitors Show Association to Serotonin-Dopamine Receptors
preprintsubmitted on 01.08.2020, 19:24 and posted on 03.08.2020, 11:16 by Burak Berber, Osman Doluca
Here we discuss the potential of targeting Dihydroorotate dehydrogenase enzyme to help treat Covid 19. Next, we present a very large scale of docking analysis using 7900 drug candidates and 20 Dihydroorotate dehydrogenase structures. Our findings not only identify 28-FDA approved candidate molecules, but also show common characteristics among the candidates, especially their association with serotonin-dopamine receptors. In continuation, we discuss the existing clinical trials for Covid 19 treatment of some of the drug candidates we have identified, supporting that the rest are good candidates.